
Surface Oncology, an immuno-oncology company developing immunotherapies that target the tumour microenvironment, has announced the appointment of Robert Ross as …

Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

